As an addendum, I had previously expressed concern on this board about how exactly planned to demonstrate cardioprotection with bisantrene. The Baker Institute study investigated these patients over 4 months, and were able to show significant functional decline in this short time frame. I'm far more confident of the trials ability to show (hopefully) a significant difference in functional decline in bis+doxo vs. doxo only treated patients now, within the short timeframe of the trial.
The planned Phase 1a/b cardioprotection study in solid tumour patients, whilst having a small sample number, should be able to provide the first signal of bisantrene's ability to protect patient's hearts in those undergoing anthracycline treatment. If the trial is successful it will have massive implications for RAC.
As an addendum, I had previously expressed concern on this board...
-
- There are more pages in this discussion • 261 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
